Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 14, 2022 07:15 ET | Source: Akouos, Inc.

Akouos Reports Third Quarter 2022 Financial Results and Provides Business Highlights

-Received clearance from FDA for the AK-OTOF IND application to initiate a Phase 1/2, first in human, pediatric clinical trial -Continued progress toward planned IND submission for AK-antiVEGF in...
September 13, 2022 07:00 ET | Source: Akouos, Inc.

Akouos Receives FDA Clearance of its IND Application for AK-OTOF, a Gene Therapy Intended for the Treatment of OTOF-mediated Hearing Loss

-The IND for AK-OTOF is the first to receive FDA clearance for a genetic form of hearing loss and the first for an AAV vector therapy with the potential to treat an inner ear condition -Akouos plans...
August 15, 2022 07:00 ET | Source: Akouos, Inc.

Akouos Reports Second Quarter 2022 Financial Results and Provides Business Highlights

Submitted IND for AK-OTOF to FDA Continued progress toward planned IND submission for AK-antiVEGF Presented new nonclinical data at ASGCT supporting the proposed clinical development of AK-OTOF and...
May 19, 2022 07:00 ET | Source: Akouos, Inc.

Akouos Presents Nonclinical Data Supporting the Planned Clinical Development of AK-OTOF and Strategies for Regulated Gene Expression in the Inner Ear at the American Society of Gene and Cell Therapy 25th Annual Meeting

- Nonclinical data demonstrate that a single intracochlear administration of an AAVAnc80 vector led to durable restoration of auditory function and was well tolerated, supporting planned clinical...
May 12, 2022 07:45 ET | Source: Akouos, Inc.

Akouos Reports First Quarter 2022 Financial Results and Provides Business Highlights

- Continued progress toward planned IND submissions for AK-OTOF in the first half of 2022 and AK-antiVEGF in 2022 - Presenting new nonclinical data at ASGCT supporting the planned clinical...
May 04, 2022 07:00 ET | Source: Akouos, Inc.

Akouos to Present at Bank of America 2022 Healthcare Conference

BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with...
May 03, 2022 07:00 ET | Source: Akouos, Inc.

Akouos to Present at the American Society of Gene and Cell Therapy 25th Annual Meeting

BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling...
March 29, 2022 08:00 ET | Source: Akouos, Inc.

Akouos Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights

- Advanced toward planned IND submissions for AK-OTOF in the first half of 2022 and AK-antiVEGF in 2022 - Presented data at ARO demonstrating potential of precision genetic medicine platform to...
March 24, 2022 07:00 ET | Source: Akouos, Inc.

Akouos to Participate in Upcoming March Virtual Investor Conferences

BOSTON, March 24, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with...
March 10, 2022 07:00 ET | Source: Akouos, Inc.

Akouos Appoints Aaron Tward, M.D., Ph.D., as Chief Scientific Officer

BOSTON, March 10, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling...